The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models European Journal of Cancer October 2022;174:S57-S58
Date
10/01/2022
DOI
10.1016/S0959-8049(22)00954-6Scopus ID
2-s2.0-85140454116 (requires institutional sign-in at Scopus site)
1 CitationAuthor List
Joe R, Matsumura Y, Siddiqui A, Foulks J, Beg M, Thompson J, Yamamoto N, Spira A, Sarantopoulos J, Melear J, Lou Y, Lebedinsky C, Li J, Watanabe A, Warner S
Author
Jonathan R. Thompson MD Assistant Professor in the Medicine department at Medical College of Wisconsin